Anne Searls De Groot

List of Publications by Year
in descending order

218 papers	6,686 citations	66343 42 h-index	85541 71 g-index
234 all docs	234 docs citations	234 times ranked	5772 citing authors

#	Article	IF	Citations
1	Immunogenicity of protein therapeutics. Trends in Immunology, 2007, 28, 482-490.	6.8	438
2	Activation of natural regulatory T cells by IgG Fcâ€“derived peptide â€œTregitopesâ€• Blood, 2008, 112, 3303-3311.	1.4	350
3	T-cell dependent immunogenicity of protein therapeutics: Preclinical assessment and mitigation. Clinical Immunology, 2013, 149, 534-555.	3.2	216
4	Reducing risk, improving outcomes: Bioengineering less immunogenic protein therapeutics. Clinical Immunology, 2009, 131, 189-201.	3.2	165
5	Immunoâ€informatics: Mining genomes for vaccine components. Immunology and Cell Biology, 2002, 80, 255-269.	2.3	153
6	From genome to vaccine: in silico predictions, ex vivo verification. Vaccine, 2001, 19, 4385-4395.	3.8	152
7	Two novel T cell epitope prediction algorithms based on MHC-binding motifs; comparison of predicted and published epitopes from Mycobacterium tuberculosis and HIV protein sequences. Vaccine, 1995, 13, 581-591.	3.8	148
8	Immunomics: discovering new targets for vaccines and therapeutics. Drug Discovery Today, 2006, 11, 203-209.	6.4	147
9	Clinical validation of the â€œin silicoâ€•prediction of immunogenicity of a human recombinant therapeutic protein. Clinical Immunology, 2007, 124, 26-32.	3.2	135
10	Emerging Vaccine Informatics. Journal of Biomedicine and Biotechnology, 2010, 2010, 1-26.	3.0	114
11	An Interactive Web Site Providing Major Histocompatibility Ligand Predictions: Application to HIV Research. AIDS Research and Human Retroviruses, 1997, 13, 529-531.	1.1	98
12	Prediction of immunogenicity: in silico paradigms, ex vivo and in vivo correlates. Current Opinion in Pharmacology, 2008, 8, 620-626.	3.5	96
13	Prediction of well-conserved HIV-1 ligands using a matrix-based algorithm, EpiMatrix. Vaccine, 1998, 16, 1880-1884.	3.8	95
14	T cell epitope: Friend or Foe? Immunogenicity of biologics in contextâ˜†. Advanced Drug Delivery Reviews, 2009, 61, 965-976.	13.7	90
15	The two-faced T cell epitope. Human Vaccines and Immunotherapeutics, 2013, 9, 1577-1586.	3.3	88
16	Immunoinformatic comparison of T-cell epitopes contained in novel swine-origin influenza A (H1N1) virus with epitopes in 2008â€“2009 conventional influenza vaccine. Vaccine, 2009, 27, 5740-5747.	3.8	86
17	iVAX: An integrated toolkit for the selection and optimization of antigens and the design of epitope-driven vaccines. Human Vaccines and Immunotherapeutics, 2015, 11, 2312-2321.	3.3	83
18	From genome to vaccineâ€”new immunoinformatics tools for vaccine design. Methods, 2004, 34, 425-428.	3.8	79

#	Article	IF	Citations
19	Analyzing Mycobacterium tuberculosis proteomes for candidate vaccine epitopes. Tuberculosis, 2005, 85, 95-105.	1.9	79
20	Low immunogenicity predicted for emerging avian-origin H7N9. Human Vaccines and Immunotherapeutics, 2013, 9, 950-956.	3.3	78
21	Better Epitope Discovery, Precision Immune Engineering, and Accelerated Vaccine Design Using Immunoinformatics Tools. Frontiers in Immunology, 2020, 11, 442.	4.8	78
22	Developing an epitope-driven tuberculosis (TB) vaccine. Vaccine, 2005, 23, 2121-2131.	3.8	76
23	HIV vaccine development by computer assisted design: the GAIA vaccine. Vaccine, 2005, 23, 2136-2148.	3.8	76
24	Genome-derived vaccines. Expert Review of Vaccines, 2004, 3, 59-76.	4.4	74
25	Tregitope update: Mechanism of action parallels IVIg. Autoimmunity Reviews, 2013, 12, 436-443.	5.8	70
26	Mapping cross-clade HIV-1 vaccine epitopes using a bioinformatics approach. Vaccine, 2003, 21, 4486-4504.	3.8	68
27	Effect of HLA DR epitope de-immunization of Factor VIII in vitro and in vivo. Clinical Immunology, 2012, 142, 320-331.	3.2	68
28	T-Cell Dependent Immunogenicity of Protein Therapeutics Pre-clinical Assessment and Mitigationâ€“Updated Consensus and Review 2020. Frontiers in Immunology, 2020, 11, 1301.	4.8	68
29	Diversity of Francisella tularensis Schu4 antigens recognized by T lymphocytes after natural infections in humans: Identification of candidate epitopes for inclusion in a rationally designed tularemia vaccine. Vaccine, 2007, 25, 3179-3191.	3.8	65
30	HelicoVax: Epitope-based therapeutic Helicobacter pylori vaccination in a mouse model. Vaccine, 2011, 29, 2085-2091.	3.8	64
31	In Vitro and In Vivo Studies of IgG-derived Treg Epitopes (Tregitopes): A Promising New Tool for Tolerance Induction and Treatment of Autoimmunity. Journal of Clinical Immunology, 2013, 33, 43-49.	3.8	61
32	In silico-accelerated identification of conserved and immunogenic variola/vaccinia T-cell epitopes. Vaccine, 2009, 27, 6471-6479.	3.8	58
33	HLA-A2-Restricted CD8 + -Cytotoxic-T-Cell Responses to Novel Epitopes in Mycobacterium tuberculosis Superoxide Dismutase, Alanine Dehydrogenase, and Glutamine Synthetase. Infection and Immunity, 2004, 72, 2412-2415.	2.2	52
34	A Cross-Sectional Study to Assess HPV Knowledge and HPV Vaccine Acceptability in Mali. PLoS ONE, 2013, 8, e56402.	2.5	52
35	Bioinformatics tools for identifying class I-restricted epitopes. Methods, 2003, 29, 289-298.	3.8	51
36	Coupling sensitive in vitro and in silico techniques to assess cross-reactive CD4+ T cells against the swine-origin H1N1 influenza virus. Vaccine, 2011, 29, 3299-3309.	3.8	51

#	Article	IF	Citations
37	An HLA-Directed Molecular and Bioinformatics Approach Identifies New HLA-A11 HIV-1 Subtype E Cytotoxic T Lymphocyte Epitopes in HIV-1-Infected Thais. AIDS Research and Human Retroviruses, 2001, 17, 703-717.	1.1	50
38	VennVax, a DNA-prime, peptide-boost multi-T-cell epitope poxvirus vaccine, induces protective immunity against vaccinia infection by T cell response alone. Vaccine, 2011, 29, 501-511.	3.8	49
39	Epitope-Driven TB Vaccine Development: A Streamlined Approach Using Immuno-Informatics, ELISpot Assays, and HLA Transgenic Mice. Current Molecular Medicine, 2007, 7, 351-363.	1.3	47
40	CHOPPI: A web tool for the analysis of immunogenicity risk from host cell proteins in CHOâ€based protein production. Biotechnology and Bioengineering, 2014, 111, 2170-2182.	3.3	47
41	Thyrotropin Receptor Epitopes and Their Relation to Histocompatibility Leukocyte Antigen-DR Molecules in Gravesâ€™ Disease. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 2286-2294.	3.6	43
42	Greater CD8+ TCR Heterogeneity and Functional Flexibility in HIV-2 Compared to HIV-1 Infection. Journal of Immunology, 2003, 171, 307-316.	0.8	42
43	Engineering immunogenic consensus T helper epitopes for a cross-clade HIV vaccine. Methods, 2004, 34, 476-487.	3.8	42
44	Identification of immunogenic HLA-B7 â€œAchillesâ€™ heelâ€•epitopes within highly conserved regions of HIV. Vaccine, 2008, 26, 3059-3071.	3.8	42
45	A call to cellular & humoral arms: Enlisting cognate T cell help to develop broad-spectrum vaccines against influenza A. Hum Vaccin, 2008, 4, 148-157.	2.4	42
46	Prediction of immunogenicity for therapeutic proteins: state of the art. Current Opinion in Drug Discovery & Development, 2007, 10, 332-40.	1.9	42
47	Prediction of HIV Peptide Epitopes by a Novel Algorithm. AIDS Research and Human Retroviruses, 1996, 12, 593-610.	1.1	41
48	Tregitope: Immunomodulation Powerhouse. Human Immunology, 2014, 75, 1139-1146.	2.4	41
49	H7N9 T-cell epitopes that mimic human sequences are less immunogenic and may induce Treg-mediated tolerance. Human Vaccines and Immunotherapeutics, 2015, 11, 2241-2252.	3.3	40
50	Immune camouflage: Relevance to vaccines and human immunology. Human Vaccines and Immunotherapeutics, 2014, 10, 3570-3575.	3.3	39
51	HCV epitope, homologous to multiple human protein sequences, induces a regulatory T cell response in infected patients. Journal of Hepatology, 2015, 62, 48-55.	3.7	39
52	Highly conserved influenza T cell epitopes induce broadly protective immunity. Vaccine, 2019, 37, 5371-5381.	3.8	39
53	Can we prevent immunogenicity of human protein drugs?. Annals of the Rheumatic Diseases, 2010, 69, i72-i76.	0.9	38
54	Modulation of CD8+ T cell responses to AAV vectors with IgG-derived MHC class II epitopes. Molecular Therapy, 2013, 21, 1727-1737.	8.2	38

#	Article	IF	Citations
55	Application of IgG-Derived Natural Treg Epitopes (IgG Tregitopes) to Antigen-Specific Tolerance Induction in a Murine Model of Type 1 Diabetes. Journal of Diabetes Research, 2013, 2013, 1-17.	2.3	37
56	Epitope-based vaccination against pneumonic tularemia. Vaccine, 2009, 27, 5299-5306.	3.8	36
57	Of [hamsters] and men. Human Vaccines and Immunotherapeutics, 2012, 8, 1172-1174.	3.3	36
58	Epitope-Based Immunome-Derived Vaccines: A Strategy for Improved Design and Safety. , 2009, , 39-69.		36
59	How the SARS vaccine effort can learn from HIV?speeding towards the future, learning from the past. Vaccine, 2003, 21, 4095-4104.	3.8	35
60	Time for T? Immunoinformatics addresses vaccine design for neglected tropical and emerging infectious diseases. Expert Review of Vaccines, 2015, 14, 21-35.	4.4	35
61	A humanized mouse model identifies key amino acids for low immunogenicity of H7N9 vaccines. Scientific Reports, 2017, 7, 1283.	3.3	35
62	Human Immunodeficiency Virus Reverse Transcriptase T Helper Epitopes Identified in Mice and Humans: Correlation with a Cytotoxic T Cell Epitope. Journal of Infectious Diseases, 1991, 164, 1058-1065.	4.0	34
63	Integrated assessment of predicted MHC binding and cross-conservation with self reveals patterns of viral camouflage. BMC Bioinformatics, 2014, 15, S1.	2.6	34
64	Immunogenicity and immune modulatory effects of in silico predictedL. donovanicandidate peptide vaccines. Human Vaccines and Immunotherapeutics, 2012, 8, 1769-1774.	3.3	33
65	Promiscuous Coxiella burnetii CD4 Epitope Clusters Associated With Human Recall Responses Are Candidates for a Novel T-Cell Targeted Multi-Epitope Q Fever Vaccine. Frontiers in Immunology, 2019, 10, 207.	4.8	33
66	Identification of Subdominant Cytotoxic T Lymphocyte Epitopes Encoded by Autologous HIV Type 1 Sequences, Using Dendritic Cell Stimulation and Computer-Driven Algorithm. AIDS Research and Human Retroviruses, 2000, 16, 67-76.	1.1	31
67	Confirmation of Immunogenic Consensus Sequence HIV-1 T-cell Epitopes in Bamako, Mali and Providence, Rhode Island. Hum Vaccin, 2006, 2, 119-128.	2.4	31
68	Regulatory T cell epitopes (Tregitopes) in IgG induce tolerance in vivo and lack immunogenicity per se. Journal of Leukocyte Biology, 2013, 94, 377-383.	3.3	31
69	Beyond humanization and de-immunization: tolerization as a method for reducing the immunogenicity of biologics. Expert Review of Clinical Pharmacology, 2013, 6, 651-662.	3.1	31
70	In Vivo Validation of Predicted and Conserved T Cell Epitopes in a Swine Influenza Model. PLoS ONE, 2016, 11, e0159237.	2.5	31
71	A Method for Individualizing the Prediction of Immunogenicity of Protein Vaccines and Biologic Therapeutics: Individualized T Cell Epitope Measure (iTEM). Journal of Biomedicine and Biotechnology, 2010, 2010, 1-7.	3.0	30
72	T cell epitope redundancy: cross-conservation of the TCR face between pathogens and self and its implications for vaccines and autoimmunity. Expert Review of Vaccines, 2016, 15, 607-617.	4.4	28

#	Article	IF	Citations
73	Evolutionary deimmunization: An ancillary mechanism for self-tolerance?. Cellular Immunology, 2006, 244, 148-153.	3.0	27
74	Knowledge, attitudes, practices and willingness to vaccinate in preparation for the introduction of HPV vaccines in Bamako, Mali. PLoS ONE, 2017, 12, e0171631.	2.5	27
75	Nucleophosmin leukaemic mutants contain C-terminus peptides that bind HLA class I molecules. Leukemia, 2008, 22, 424-426.	7.2	25
76	Immunome-derived vaccines. Expert Opinion on Biological Therapy, 2004, 4, 767-772.	3.1	24
77	Immunization with cross-conserved H1N1 influenza CD4+T-cell epitopes lowers viral burden in HLA DR3 transgenic mice. Human Vaccines and Immunotherapeutics, 2013, 9, 2060-2068.	3.3	24
78	Potential Application of Tregitopes as Immunomodulating Agents in Multiple Sclerosis. Neurology Research International, 2011, 2011, 1-6.	1.3	23
79	Universal H1N1 influenza vaccine development. Human Vaccines and Immunotherapeutics, 2013, 9, 1598-1607.	3.3	23
80	VaxCelerate II: Rapid development of a self-assembling vaccine for Lassa fever. Human Vaccines and Immunotherapeutics, 2014, 10, 3022-3038.	3.3	23
81	Aspartate-Î²-hydroxylase induces epitope-specific T cell responses in hepatocellular carcinoma. Vaccine, 2015, 33, 1256-1266.	3.8	23
82	Highly conserved, non-human-like, and cross-reactive SARS-CoV-2 T cell epitopes for COVID-19 vaccine design and validation. Npj Vaccines, 2021, 6, 71.	6.0	23
83	Molecular Epidemiology of HIV-1 Infection in the Philippines, 1985 to 1997: Transmission of Subtypes B and E and Potential Emergence of Subtypes C and F. Journal of Acquired Immune Deficiency Syndromes, 1998, 18, 260-269.	0.3	22
84	Rapid Determination of HLA B*07 Ligands from the West Nile Virus NY99 Genome. Emerging Infectious Diseases, 2001, 7, 706-713.	4.3	22
85	Cross-conservation of T-cell epitopes. Human Vaccines and Immunotherapeutics, 2014, 10, 256-262.	3.3	22
86	Community-based childhood obesity prevention intervention for parents improves health behaviors and food parenting practices among Hispanic, low-income parents. BMC Obesity, 2018, 5, 11.	3.1	22
87	Novel function of complement C3d as an autologous helper Tâ€cell target. Immunology and Cell Biology, 2008, 86, 221-225.	2.3	21
88	From Immunome to Vaccine: Epitope Mapping and Vaccine Design Tools. Novartis Foundation Symposium, 2008, , 57-76.	1.1	21
89	Peptide-pulsed dendritic cells induce the hepatitis C viral epitope-specific responses of naÃ¯ve human T cells. Vaccine, 2014, 32, 3285-3292.	3.8	21
90	C3d adjuvant effects are mediated through the activation of C3dâ€specific autoreactive T cells. Immunology and Cell Biology, 2015, 93, 189-197.	2.3	21

#	Article	IF	Citations
91	An immunoinformatics-derived DNA vaccine encoding human class II T cell epitopes of Ebola virus, Sudan virus, and Venezuelan equine encephalitis virus is immunogenic in HLA transgenic mice. Human Vaccines and Immunotherapeutics, 2017, 13, 2824-2836.	3.3	21
92	Therapeutic administration of Tregitope-Human Albumin Fusion with Insulin Peptides to promote Antigen-Specific Adaptive Tolerance Induction. Scientific Reports, 2019, 9, 16103.	3.3	20
93	HIV-1 Vaccine Trials: Evolving Concepts and Designs. Open AIDS Journal, 2012, 6, 274-288.	0.5	20
94	Efficacy of novel plasmid DNA encoding vaccinia antigens in improving current smallpox vaccination strategy. Vaccine, 2006, 24, 4461-4470.	3.8	19
95	Putting immunoinformatics to the test. Nature Biotechnology, 2006, 24, 791-792.	17.5	19
96	Making vaccines â€œon demandâ€• Human Vaccines and Immunotherapeutics, 2013, 9, 1877-1884.	3.3	19
97	De-immun ized and F unctional T herapeutic (DeFT) versions of a long lasting recombinant alpha interferon for antiviral therapy. Clinical Immunology, 2017, 176, 31-41.	3.2	19
98	The Role of Glutamic or Aspartic Acid in Position Four of the Epitope Binding Motif and Thyrotropin Receptor-Extracellular Domain Epitope Selection in Gravesâ€™ Disease. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 2909-2916.	3.6	18
99	Adeno-associated virus mediated delivery of Tregitope 167 ameliorates experimental colitis. World Journal of Gastroenterology, 2012, 18, 4288.	3.3	18
100	Vida Sana: A Lifestyle Intervention for Uninsured, Predominantly Spanish-Speaking Immigrants Improves Metabolic Syndrome Indicators. Journal of Community Health, 2015, 40, 116-123.	3.8	18
101	T cell epitope content comparison (EpiCC) analysis demonstrates a bivalent PCV2 vaccine has greater T cell epitope overlap with field strains than monovalent PCV2 vaccines. Veterinary Immunology and Immunopathology, 2020, 223, 110034.	1.2	18
102	New tools, new approaches and new ideas for vaccine development. Expert Review of Vaccines, 2007, 6, 125-127.	4.4	17
103	Teaching tolerance. Human Vaccines and Immunotherapeutics, 2012, 8, 1459-1464.	3.3	17
104	Tregitope Peptides: The Active Pharmaceutical Ingredient of IVIG?. Clinical and Developmental Immunology, 2013, 2013, 1-6.	3.3	17
105	Mass spectrometry-assisted identification of ADAMTS13-derived peptides presented on HLA-DR and HLA-DQ. Haematologica, 2018, 103, 1083-1092.	3.5	17
106	Immune escape and immune camouflage may reduce the efficacy of RTS,S vaccine in Malawi. Human Vaccines and Immunotherapeutics, 2020, 16, 214-227.	3.3	17
107	Neoantigen-based personalized cancer vaccines: the emergence of precision cancer immunotherapy. Expert Review of Vaccines, 2022, 21, 173-184.	4.4	17
108	Identification of genome-derived vaccine candidates conserved between human and mouse-adapted strains ofH. pylori. Hum Vaccin, 2008, 4, 219-223.	2.4	16

#	Article	IF	Citations
109	Elevated antigen-specific Th2 type response is associated with the poor prognosis of hand, foot and mouth disease. Virus Research, 2013, 177, 62-65.	2.2	16
110	Development and validation of an epitope prediction tool for swine (PigMatrix) based on the pocket profile method. BMC Bioinformatics, 2015, 16, 290.	2.6	16
111	In silico identification and modification of T cell epitopes in pertussis antigens associated with tolerance. Human Vaccines and Immunotherapeutics, 2020, 16, 277-285.	3.3	16
112	Human Immune Responses to H. pylori HLA Class II Epitopes Identified by Immunoinformatic Methods. PLoS ONE, 2014, 9, e94974.	2.5	16
113	Tâ€cell epitope content comparison (Epi‹scp›CC‹/scp›) of swine H1 influenza A virus hemagglutinin. Influenza and Other Respiratory Viruses, 2017, 11, 531-542.	3.4	15
114	HLA- and genotype-based risk assessment model to identify infantile onset pompe disease patients at high-risk of developing significant anti-drug antibodies (ADA). Clinical Immunology, 2019, 200, 66-70.	3.2	15
115	A Dominant EV71-Specific CD4+ T Cell Epitope Is Highly Conserved among Human Enteroviruses. PLoS ONE, 2012, 7, e51957.	2.5	15
116	Risks for HIV Infection in Incarcerated Women. Journal of Women's Health, 1995, 4, 569-577.	0.9	14
117	In silico predictions; in vivo veritas. Nature Biotechnology, 1999, 17, 533-534.	17.5	14
118	T cell epitope identification for bovine vaccines: an epitope mapping method for BoLA A-11. International Journal for Parasitology, 2003, 33, 641-653.	3.1	14
119	Preclinical development of HIvax: Human survivin highly immunogenic vaccines. Human Vaccines and Immunotherapeutics, 2015, 11, 1585-1595.	3.3	14
120	A prime-boost concept using a T-cell epitope-driven DNA vaccine followed by a whole virus vaccine effectively protected pigs in the pandemic H1N1 pig challenge model. Vaccine, 2019, 37, 4302-4309.	3.8	14
121	Self-Replicating RNAs Drive Protective Anti-tumor T Cell Responses to Neoantigen Vaccine Targets in a Combinatorial Approach. Molecular Therapy, 2021, 29, 1186-1198.	8.2	14
122	Immunogenic Consensus Sequence T helper Epitopes for a Pan-Burkholderia Biodefense Vaccine. Immunome Research, 2011, 7, .	0.1	14
123	Further progress on defining highly conserved immunogenic epitopes for a global HIV vaccine: HLA-A3-restricted GAIA vaccine epitopes. Human Vaccines and Immunotherapeutics, 2012, 8, 987-1000.	3.3	13
124	Conservation of HIV-1 T cell epitopes across time and clades: Validation of immunogenic HLA-A2 epitopes selected for the GAIA HIV vaccine. Vaccine, 2012, 30, 7547-7560.	3.8	13
125	Smarter vaccine design will circumvent regulatory T cell-mediated evasion in chronic HIV and HCV infection. Frontiers in Microbiology, 2014, 5, 502.	3.5	13
126	Harnessing the power of genomics and immunoinformatics to produce improved vaccines. Expert Opinion on Drug Discovery, 2011, 6, 9-15.	5.0	12

#	Article	IF	Citations
127	New vaccines needed for pathogens infecting animals and humans. Human Vaccines and Immunotherapeutics, 2012, 8, 971-978.	3.3	12
128	A Nurse-Run Walk-In Clinic: Cost-Effective Alternative to Non-urgent Emergency Department Use by the Uninsured. Journal of Community Health, 2013, 38, 1042-1049.	3.8	12
129	Dendritic Cell-Mediated, DNA-Based Vaccination against Hepatitis C Induces the Multi-Epitope-Specific Response of Humanized, HLA Transgenic Mice. PLoS ONE, 2014, 9, e104606.	2.5	12
130	An immunoinformatic approach for identification of Trypanosoma cruzi HLA-A2-restricted CD8⁺T cell epitopes. Human Vaccines and Immunotherapeutics, 2015, 11, 2322-2328.	3.3	12
131	Tregitopes Improve Asthma by Promoting Highly Suppressive and Antigen-Specific Tregs. Frontiers in Immunology, 2021, 12, 634509.	4.8	12
132	Prevalence of HPV 16 and 18 and attitudes toward HPV vaccination trials in patients with cervical cancer in Mali. PLoS ONE, 2017, 12, e0172661.	2.5	11
133	A comparison of two methods for T cell epitope mapping: ?cell free? in vitro versus immunoinformatics. Immunome Research, 2011, 7, .	0.1	10
134	Computational vaccinology and the ICoVax 2012 workshop. BMC Bioinformatics, 2013, 14, I1.	2.6	10
135	Epitope Recognition in HLA-DR3 Transgenic Mice Immunized to TSH-R Protein or Peptides. Endocrinology, 2013, 154, 2234-2243.	2.8	10
136	T cell epitope engineering: an avian H7N9 influenza vaccine strategy for pandemic preparedness and response. Human Vaccines and Immunotherapeutics, 2018, 14, 2203-2207.	3.3	10
137	Coxiella burnetii Epitope-Specific T-Cell Responses in Patients with Chronic Q Fever. Infection and Immunity, 2019, 87, .	2.2	10
138	Design of a multiepitopic Zaire ebolavirus protein and its expression in plant cells. Journal of Biotechnology, 2019, 295, 41-48.	3.8	10
139	Novel multiparameter correlates of Coxiella burnetii infection and vaccination identified by longitudinal deep immune profiling. Scientific Reports, 2020, 10, 13311.	3.3	10
140	Identification of a potent regulatory T cell epitope in factor V that modulates CD4+ and CD8+ memory T cell responses. Clinical Immunology, 2021, 224, 108661.	3.2	10
141	Immune Tolerance-Adjusted Personalized Immunogenicity Prediction for Pompe Disease. Frontiers in Immunology, 2021, 12, 636731.	4.8	10
142	MovingHelicobacter pylorivaccine development forward with bioinformatics and immunomics. Expert Review of Vaccines, 2012, 11, 1031-1033.	4.4	9
143	New Immunoinformatics Tools for Swine: Designing Epitope-Driven Vaccines, Predicting Vaccine Efficacy, and Making Vaccines on Demand. Frontiers in Immunology, 2020, 11, 563362.	4.8	9
144	From immunome to vaccine: epitope mapping and vaccine design tools. Novartis Foundation Symposium, 2003, 254, 57-72; discussion 72-6, 98-101, 250-2.	1.1	9

#	Article	IF	Citations
145	Development of a novel fully functional coagulation factor VIII with reduced immunogenicity utilizing an in silico prediction and deimmunization approach. Journal of Thrombosis and Haemostasis, 2021, 19, 2161-2170.	3.8	8
146	Development of highly stable and de-immunized versions of recombinant alpha interferon: Promising candidates for the treatment of chronic and emerging viral diseases. Clinical Immunology, 2021, 233, 108888.	3.2	8
147	Identification and retrospective validation of T-cell epitopes in the hepatitis C virus genotype 4 proteome. Human Vaccines and Immunotherapeutics, 2014, 10, 2366-2377.	3.3	7
148	Multi-antigen Vaccination With Simultaneous Engagement of the OX40 Receptor Delays Malignant Mesothelioma Growth and Increases Survival in Animal Models. Frontiers in Oncology, 2019, 9, 720.	2.8	7
149	Differential functional patterns of memory CD4+ and CD8+ T-cells from volunteers immunized with Ty21a typhoid vaccine observed using a recombinant Escherichia coli system expressing S. Typhi proteins. Vaccine, 2020, 38, 258-270.	3.8	7
150	Immune-engineered H7N9 influenza hemagglutinin improves protection against viral influenza virus challenge. Human Vaccines and Immunotherapeutics, 2020, 16, 2042-2050.	3.3	7
151	An Integrated Genomic and Immunoinformatic Approach to H. pylori Vaccine Design. Immunome Research, 2011, 7, .	0.1	7
152	Tularemia vaccines - an overview. Medicine and Health, Rhode Island, 2007, 90, 311-4.	0.1	7
153	HPV knowledge and vaccine acceptance in an uninsured Hispanic population in Providence, RI. Rhode Island Medical Journal (2013), 2014, 97, 35-9.	0.2	7
154	Evaluation of a Human T Cell-Targeted Multi-Epitope Vaccine for Q Fever in Animal Models of Coxiella burnetii Immunity. Frontiers in Immunology, 2022, 13, .	4.8	7
155	Co-infection with Mycobacterium tuberculosis and HIV in high risk clinical care settings in Rhode Island. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 1998, 10, 221-229.	1.2	6
156	Analysis of ChimeriVax Japanese Encephalitis Virus envelope for T-cell epitopes and comparison to circulating strain sequences. Vaccine, 2007, 25, 8077-8084.	3.8	6
157	Do Tregitopes have the potential to impact the current treatment landscape of autoimmune diseases?. Expert Review of Clinical Immunology, 2013, 9, 1155-1157.	3.0	6
158	Partial pathogen protection by tick-bite sensitization and epitope recognition in peptide-immunized HLA DR3 transgenic mice. Human Vaccines and Immunotherapeutics, 2014, 10, 3048-3059.	3.3	6
159	Hit-and-run, hit-and-stay, and commensal bacteria present different peptide content when viewed from the perspective of the T cell. Vaccine, 2015, 33, 6922-6929.	3.8	6
160	Agility in adversity: Vaccines on Demand. Expert Review of Vaccines, 2016, 15, 1087-1091.	4.4	6
161	Adherence to American Diabetes Association guidelines in a volunteer-run free clinic for the uninsured: better than standards achieved by clinics for insured patients. Rhode Island Medical Journal (2013), 2013, 96, 25-9.	0.2	6
162	Prevalence of Prior Sexual Abuse and HIV Risk-taking Behaviors in Incarcerated Women in Massachusetts. Journal of Correctional Health Care, 1995, 2, 137-149.	0.5	5

#	Article	IF	Citations
163	Vaccine Informatics. Journal of Biomedicine and Biotechnology, 2010, 2010, 1-2.	3.0	5
164	Use of Bioinformatics to Predict MHC Ligands and T-Cell Epitopes. Methods in Microbiology, 2010, 37, 35-66.	0.8	5
165	Recruitment, Training, and Roles of the Bilingual, Bicultural Navegantes: Developing a Specialized Workforce of Community Health Workers to Serve a Low-Income, Spanish-Speaking Population in Rhode Island. Frontiers in Public Health, 2021, 9, 666566.	2.7	5
166	Modelling the immunogenicity of therapeutic proteins using T cell epitope mapping. Developments in Biologicals, 2003, 112, 71-80.	0.5	5
167	Exploring the immunome: A brave new world for human vaccine development. Hum Vaccin, 2009, 5, 790-793.	2.4	4
168	Species neutral correlates of immunogenicity for vaccines and protein therapeutics: Fact or Science Fiction. Hum Vaccin, 2010, 6, 368-372.	2.4	4
169	Multi-step screening of neoantigensâ€™ HLA- and TCR-interfaces improves prediction of survival. Scientific Reports, 2021, 11, 9983.	3.3	4
170	Identification and Immune Assessment of T Cell Epitopes in Five Plasmodium falciparum Blood Stage Antigens to Facilitate Vaccine Candidate Selection and Optimization. Frontiers in Immunology, 2021, 12, 690348.	4.8	4
171	Suppression of CTL Responses against AAV-Capsid Epitopes by Peptide-Induced Regulatory T Cells.. Blood, 2009, 114, 377-377.	1.4	4
172	Challenges and opportunities for HIV care in jails and prisons in the United States. International Journal of Prisoner Health, 2006, 2, 173-191.	0.9	3
173	Time for T? Thoughts about the 2009 novel H1N1 influenza outbreak and the role of T cell epitopes in the next generation of influenza vaccines. Hum Vaccin, 2010, 6, 157-163.	2.4	3
174	Community clinic-based lifestyle change for prevention of metabolic syndrome: Rationale, design and methods of the â€˜Vida Sana/healthy lifeâ€™ program. Contemporary Clinical Trials Communications, 2018, 12, 123-128.	1.1	3
175	Quantifying the Persistence of Vaccine-Related T Cell Epitopes in Circulating Swine Influenza A Strains from 2013â€“2017. Vaccines, 2021, 9, 468.	4.4	3
176	Bridging Computational Vaccinology and Vaccine Development Through Systematic Identification, Characterization, and Downselection of Conserved and Variable Circumsporozoite Protein CD4 T Cell Epitopes From Diverse Plasmodium falciparum Strains. Frontiers in Immunology, 2021, 12, 689920.	4.8	3
177	A Standard of HIV Care for Incarcerated Women: Northeastern United Statesâ€™ Experiences. Journal of Correctional Health Care, 1998, 5, 139-177.	0.5	2
178	The measles campaign in West and Central Africa: Remembering the future. Vaccine, 2008, 26, 3783-3786.	3.8	2
179	Immunome-derived Epitope-driven Vaccines (ID-EDV) Protect against Viral or Bacterial Challenge in Humanized Mice. Procedia in Vaccinology, 2009, 1, 15-22.	0.4	2
180	Report from the field. Human Vaccines and Immunotherapeutics, 2012, 8, 1006-1009.	3.3	2

#	Article	IF	Citations
181	Knowledge/attitude/practices of HPV & cervical cancer, willingness to participate in vaccine trial in preparation for HIV & HPV vaccine trials in Mali. Retrovirology, 2012, 9, .	2.0	2
182	ICoVax 2013: The 3rd ISV Pre-conference Computational Vaccinology Workshop. BMC Bioinformatics, 2014, 15, I1.	2.6	2
183	Novel Methods for Addressing Immunogenicity of Therapeutic Enzymes. AAPS Advances in the Pharmaceutical Sciences Series, 2015, , 63-77.	0.6	2
184	Immunoinformatics: The Next Step in Vaccine Design. , 2010, , 223-244.		2
185	Abstract 943: Filtering out self-like neoantigens improves immune response to cancer vaccines. Cancer Research, 2019, 79, 943-943.	0.9	2
186	Introduction to the Compendium. Journal of Correctional Health Care, 1998, 5, 125-128.	0.5	1
187	Critical Prevention, Critical Care: Gynecological and Obstetrical Aspects of Comprehensive HIV Prevention and Treatment Among Incarcerated Women. Journal of Correctional Health Care, 1998, 5, 201-223.	0.5	1
188	Use of bioinformatics to predict MHC ligands and T-cell epitopes: Application to epitope-driven vaccine design. Methods in Microbiology, 2002, 32, 99-123.	0.8	1
189	Immunoinformatics Applied to Modifying and Improving Biological Therapeutics. , 2008, , 109-131.		1
190	Mycobacterium tuberculosis. , 2009, , 1219-1239.		1
191	P15-07. Knowledge, attitudes, practices and willingness to participate in HIV vaccine trials among urban residents of Bamako, Mali, in West Africa, 2005â€“2009. Retrovirology, 2009, 6, .	2.0	1
192	Four Years of CHEER: Cost and QALY Savings of a Free Nurse-run Walk-in Clinic Serving an Uninsured, Predominantly Spanish-speaking Immigrant Population in Providence. Journal of Health Care for the Poor and Underserved, 2019, 30, 806-819.	0.8	1
193	Exploit T cell Immunity for Rapid, Safe and Effective COVID-19 Vaccines. Expert Review of Vaccines, 2020, 19, 781-784.	4.4	1
194	European Immunogenicity Platform 11th Open Scientific Symposium on immunogenicity of biopharmaceuticals. Bioanalysis, 2020, 12, 1043-1048.	1.5	1
195	Legacy of light for women living with HIV in prison. Lancet, The, 1999, 353, 1107-1108.	13.7	0
196	A Novel Compound for the Treatment of Allergy and Autoimmune Diseases. Journal of Allergy and Clinical Immunology, 2009, 123, S139-S139.	2.9	0
197	P17-26. Effective design of T-cell driven vaccines applied to the GAIA HIV vaccine: advances in vaccine design based on current preclinical success. Retrovirology, 2009, 6, .	2.0	0
198	Immunoinformatic-drivenH. pylorivaccine design. , 2010, , .		0

#	Article	IF	Citations
199	Immunoinformatic approach to a multi-pathogen genome-derived epitope-driven vaccine. , 2010, , .		0
200	Immunoinformatic discovery of potential cross-reactive T cell epitopes in the measles genome. , 2011, , .		0
201	Fifth Vaccine Renaissance introduction. Human Vaccines and Immunotherapeutics, 2012, 8, 960-960.	3.3	0
202	Immunoinformatic analysis of Chinese hamster ovary (CHO) protein contaminants in therapeutic protein formulations. , 2012, , .		0
203	Further confirmation of broadly conserved, highly immunogenic cross-clade HIV CTL epitopes for inclusion in the GAIA HIV vaccine. Retrovirology, 2012, 9, .	2.0	0
204	HIV-free children born to HIV-seropositive mothers in Bamako, Mali: a six-year perspective on providing MTCTP at the front line of AIDS. Retrovirology, 2012, 9, P212.	2.0	0
205	Conservation of HIV-1 T cell epitopes across time and clades: validation of immunogenic HLA-A2 epitopes selected for the GAIA HIV vaccine. Retrovirology, 2012, 9, .	2.0	0
206	Su1829 Bioinformatic Approach to Mapping Global H. pylori cagA Sequences for Targeted Vaccine Development. Gastroenterology, 2015, 148, S-528.	1.3	0
207	3 Immunogenicity of H. pylori's CagA-Derived Peptides for Future Vaccine Development. Gastroenterology, 2016, 150, S1.	1.3	0
208	Clinical outcomes of a community clinic-based lifestyle change program for prevention and management of metabolic syndrome: Results of the â€˜Vida Sana/Healthy Lifeâ€™ program. PLoS ONE, 2021, 16, e0248473.	2.5	0
209	Identification, Selection and Immune Assessment of Liver Stage CD8 T Cell Epitopes From Plasmodium falciparum. Frontiers in Immunology, 2021, 12, 684116.	4.8	0
210	De-Immunization of Human Factor VIII: Identification of Epitopes in the C2 Domain. Blood, 2008, 112, 1030-1030.	1.4	0
211	IgG-Derived Tregitope Peptides Suppress T Cell Responses in Vitro and in Vivo. Blood, 2008, 112, 677-677.	1.4	0
212	Reducing Protein Immunogenicity by Design: Deimmunization and Tolerance Induction. , 2012, , 525-534.		0
213	Coagulation Factor VIII with Reduced Immunogenicity via a Direct De-immunization Approach. , 2019, 39, .		0
214	Abstract B089: Application of precision cancer immunotherapy design tools to bladder cancer: Non-self-like neoepitopes as a prognostic biomarker. , 2019, , .		0
215	Quantifying quality of care at a PA student-led free diabetes clinic. JAAPA: Official Journal of the American Academy of Physician Assistants, 2020, 33, 1-1.	0.3	0
216	Species neutral correlates of immunogenicity for vaccines and protein therapeutics: fact or science fiction. Hum Vaccin, 2010, 6, 371-2.	2.4	0

#	Article	IF	Citations
217	Abstract 943: Filtering out self-like neoantigens improves immune response to cancer vaccines. , 2019, , .		0
218	Novel H7N9 influenza immunogen design enhances mobilization of seasonal influenza T cell memory in H3N2 pre-immune mice. Human Vaccines and Immunotherapeutics, 2022, 18, .	3.3	0